Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells - Wikidata - awgldk - TriplyDB

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

http://www.wikidata.org/entity/Q27653836

about

The PCSK9 decade Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor Large scale association analysis identifies three susceptibility loci for coronary artery disease Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.Chronic social defeat stress disrupts regulation of lipid synthesis Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Role of an intramolecular contact on lipoprotein uptake by the LDL receptor Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.PCSK9 is a critical regulator of the innate immune response and septic shock outcome.Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

P2860

Q24615397-4ECA85D1-90C2-4488-865D-3D7B8CB69E45 Q24652495-88511624-AB80-4B3E-87C5-09C67ADB38D1 Q26786549-F616F514-A66B-4FCC-A881-57E834480EEF Q27009477-1D7532D2-BEC9-4CAD-9D5B-26D2E67C76D9 Q27013494-B3359F70-A0D2-4178-8B29-FD990908C107 Q27339783-71055FBF-ACE0-4F7E-9BCE-1E494D3E8D6B Q27655476-DFCD2CA1-E3BF-4D4E-BDEF-FE7A7108C119 Q27665195-30DAD266-A12A-4A96-AFAA-2421C994F8AF Q27680601-566DB005-668D-4B90-8A93-A5EC5A19EC9D Q28740844-032657F4-27C9-471B-A9C8-74C8873870DE Q30426857-E5B19800-DB52-42B3-93C6-B28D98CB8450 Q33532964-BA75625C-F245-4D73-BB52-3364C63AE2D2 Q33577851-F57E5162-093E-4B52-B27A-9310ABE3B731 Q33599961-A564EFA2-8F90-48DE-9C01-048C86433D36 Q34053143-86F4C81D-D351-4D42-8710-EE27FC4276AB Q34355679-868730B1-8A12-4953-ACE0-8C7915957306 Q34455663-C7578230-F889-411D-A6A2-6AE28BA08B3A Q34458693-E91A8022-C23A-4064-A487-AA9F8AFB8E63 Q34479132-1B4E0564-D2E4-4C61-ADAF-859BEFB227F7 Q34559843-CCC414B6-5113-4CE8-AEF4-4884AFA8EC96 Q34559944-81D98C76-1381-4FD1-89D4-C6DB75B77F5F Q34560763-7081E950-D5FE-4D68-ACE7-6FCB21B4E121 Q34568486-19053F5A-A94A-4AB0-94A1-1A5E01A845A6 Q34662589-77CACC95-D8A6-4356-973A-39BC5163ABAE Q34975192-C24FC144-2B0F-4CE7-B762-59F4A02D74CD Q35096270-CECCFCE1-1DB8-4B44-9F43-99CD6EDED7F6 Q35125516-0DD99CDA-C25D-4A07-9823-C3DD0F40451B Q35442741-F531438A-20F1-4976-BA0D-0F1110E3CE73 Q35612555-A948AA31-98C8-4A78-92AC-F969EA83D764 Q35883857-157E4F3C-0C56-4DD8-B9AB-2F910429B103 Q35927759-614BE34F-25F3-428A-B19E-0D84D66FF57E Q37173897-3CB25FB0-4E77-447B-AFEF-29A817F912AC Q37225018-717DF291-DDE2-482D-A87B-EFBFF0FAE65F Q37466735-190BCCDE-6709-4E08-92F3-8253FA6BE902 Q37688760-D0075021-4C8E-4FDD-8489-9969DF0F65A9 Q37724743-4B4829AF-37EA-4B29-9C36-8CBC7E77403A Q37789741-1E679437-6C81-4CFA-8152-6528855CE4BE Q37825903-3C2AB241-398E-49FA-ADA8-F1C28EB84B8E Q38075818-E79682F0-2A66-43CA-A12A-75B5B77B8A5A Q38151675-90465D6F-ED7D-4F55-958A-66440346AFDE

P2860

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

http://www.wikidata.org/entity/Q27653836

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@ast

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@en

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@nl

type

label

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@ast

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@en

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@nl

prefLabel

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@ast

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@en

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@nl

P1433

Q27653836-1E57F895-874D-46FD-BE85-B8EDF173B371

P1476

Q27653836-0E01ACC3-B7E0-4C7A-8027-8220AB97A9ED

P2093

Q27653836-902810FA-D1A7-4BFA-98B2-541BADF13455

Q27653836-BAE88D6E-29F9-4FB1-9D85-DB513017CDF6

Q27653836-BB19E8B4-A5A2-494A-89D1-DED46BF22B88

Q27653836-C1B79E22-7A25-45C9-8237-46C1BBEBCACB

Q27653836-DB460B79-BF0C-47F2-8F3F-3ED716294D95

Q27653836-DE71DE22-F27C-4FFB-A225-1C6F37227B1A

P2860

Q27653836-03B72284-6502-4F83-A1EA-A3A3151D5433

Q27653836-06217B45-29F3-4D7A-B611-6523C123397E

Q27653836-06344923-0DF8-4BB1-BD2E-4426EBDC7CD9

Q27653836-072D2DE7-97B1-44C5-ADA3-862535F700ED

Q27653836-08A054C6-35DF-4F9A-82E8-A785FA91DEC3

Q27653836-0BAF779D-AFA1-40C5-B1B4-96F338D1B3F1

Q27653836-15E3D98E-9538-4B1D-A00F-86B2F9572553

Q27653836-1635DD7B-7F3E-416A-8954-C867C7DD832D

Q27653836-1660ECDD-F828-42F5-A7C3-227F83E3C24C

Q27653836-24E1C91C-D7C6-4FAC-978C-BED53E602880

P304

Q27653836-FD8D8154-334E-48F4-B9E5-B0456D220C68

P31

Q27653836-421E5E5D-CD01-4342-A0D7-463474527BC3

P3181

Q27653836-3D725964-18DD-4F0E-B9BE-172BDA3B0DA3

P356

Q27653836-F2A55917-4F2E-423F-982E-1BE3E963875B

P407

Q27653836-036173DF-1906-423D-9471-0C0CD90D166F

P433

Q27653836-F578C506-D0FC-4777-B633-483C1EA85D7E

P478

Q27653836-0382A150-45F7-4689-B977-395D86B7FBFD

P577

Q27653836-04A14F30-FF84-40D6-BE0F-8BAA5733A454

P698

Q27653836-24F3B33C-9ED8-4C36-9667-98DA685329FA

P921

Q27653836-738D549E-5BDE-4B9F-9E62-BB0476C96615

Q27653836-A4831D6A-ED8F-4C35-9315-BFC87EE3E439

P932

Q27653836-8095090B-6926-4586-A651-9FD7C23B7775

P3181

P356

P1433

Journal of Biological Chemistry

P1476

Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells

@en

P2093

Chiyuan Chen

http://www.w3.org/2001/XMLSchema#string

Hyock Joo Kwon

http://www.w3.org/2001/XMLSchema#string

Jay D Horton

http://www.w3.org/2001/XMLSchema#string

Justin R Chen

http://www.w3.org/2001/XMLSchema#string

Markey C McNutt

http://www.w3.org/2001/XMLSchema#string

Thomas A Lagace

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Functional characterization of Narc 1, a novel proteinase related to proteinase K

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Processing of X-ray diffraction data collected in oscillation mode

Molecular biology of PCSK9: its role in LDL metabolism

Structure of the LDL receptor extracellular domain at endosomal pH

P304

10561-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

913458

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M808802200

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19224862

http://www.w3.org/2001/XMLSchema#string

P921

P932

2667743

http://www.w3.org/2001/XMLSchema#string